Cite
HARVARD Citation
Bottomley, A. et al. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet oncology. 22 (5), pp. 655-664. [Online].